North America Gastrointestinal Drugs Market Forecast to 2027 - COVID-19 Impact and Regional Analysis by Drug Class (Acid Neutralizers, Antidiarrheal and Laxatives, Anti-Inflammatory Drugs, Antiemetic and Antinauseants, Biologics, and Others); Route of Administration (Oral, and Parenteral); Application (Inflammatory Ulcerative Colitis, Crohn's Disease, Irritable Bowel Syndrome, Gastroenteritis, Celiac Disease, and Others); and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Country
Gastrointestinal drugs include promotility drugs, antimotility drugs, and drugs for acid-related disorders. The generally used gastrointestinal drugs as a group are considered safe. Gastrointestinal (GI) disease affects the stomach, pancreas, rectum and large intestine, esophagus, small intestine, gallbladder, and liver. The main symptoms of gastrointestinal disorders are indigestion, heartburn, constipation bloating, and so on.
Market Overview and Dynamics
The North America gastrointestinal drugs market is expected to reach US$ 31,664.45 million by 2027 from US$ 21,292.53 million in 2019. The market is anticipated to grow at a CAGR of 5.2% during 2019–2027. The rising prevalence of gastrointestinal (GI) diseases, and increase in development of biologics are the major factors expected to boost the growth of the gastrointestinal drugs market in North America. However, the market is likely to get impacted by the risk factor such as side effects associated with the drugs during the forecast period.
Key Market Segments
In terms of drug class, the acid neutralizers segment accounted for the largest share of the North America gastrointestinal drugs market in 2019. In terms of route of administration, oral segment accounted for the largest share of the North America gastrointestinal drugs market in 2019. In terms of application, the inflammatory ulcerative colitis segment accounted for the largest share of the North America gastrointestinal drugs market in 2019. In terms of distribution channel, the retail pharmacies segment accounted for the largest share of the North America gastrointestinal drugs market in 2019.
Major Sources and Companies Listed
Several major primary and secondary sources associated with the North America gastrointestinal drugs market report are the World Health Organization (WHO), National Health Interview Survey, Canadian Digestive Health Foundation (CDHF), Centers of Disease Control and Prevention (CDC), International Foundation for Gastrointestinal Disorders, Crohn’s & Colitis Foundation of America, National Institutes of Health (NIH) and others.
NORTH AMERICA GASTROINTESTINAL DRUGS MARKET SEGMENTATION
By Drug Class
Antidiarrheal and Laxatives
Antiemetic and Antinauseants
By Route of Administration
Inflammatory Ulcerative Colitis
Irritable Bowel Syndrome
By Distribution Channel
Johnson and Johnson Services, Inc.
LEXICON PHARMACEUTICALS, INC
Takeda Pharmaceutical Company Limited
Reasons to Buy
Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the North America gastrointestinal drugs market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America gastrointestinal drugs market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth regional market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook